Advances in Using Stem Cells to Treat Neural Diseases
暫譯: 幹細胞在神經疾病治療中的進展

這本書深入探討幹細胞研究的前沿，揭示幹細胞技術在神經再生方面的巨大潛力。這本綜合性著作提供了有關使用幹細胞研究神經退行性疾病和神經發展障礙的多種策略的寶貴見解，以及神經再生策略研究的最新進展。

《幹細胞在神經疾病治療中的進展》包含了一系列由該領域的領先專家精心策劃的章節。這些章節探討了幹細胞研究所取得的進展，並強調了在細胞重編程和組織工程方面的最新進展，以開發疾病模型和再生療法來研究和治療神經障礙。這本書提供了幹細胞研究當前狀況的無與倫比的快照，以及可能徹底改變該領域的新興技術概述。這一獨特的資源將為幹細胞生物學家、神經科學家、組織工程師、分子生物學家，以及對神經再生感興趣的學生、學者和臨床醫生提供重要的參考。

Associate Professor Raymond Wong is a Principal Investigator at the Centre for Eye Research Australia (CERA) and the Department of Ophthalmology at the University of Melbourne. He is a stem cell biologist with 20+ years of research experience, specialising in cellular reprogramming and stem cells in eye research. He completed his PhD in stem cell biology at Monash University and was awarded a California Institute of Regenerative Medicine Fellowship to pursue overseas postdoctoral training at the University of California Irvine (USA), and a Visiting Fellow Award to train at the National Institutes of Health (USA). In 2013, A/Prof Wong joined CERA with the support of a Cranborne Foundation Fellowship and a MAWA Fellowship. He's also Founder and CSO of Mirugen - a retinal gene therapy start-up. A/Prof Wong has co-authored 95 peer-reviewed publications in the fields of stem cell and eye research. Currently his research focuses on using stem cells and gene therapy to treat retinal degeneration.

Dr. Yohei Hayashi is a unit leader at the Research and Development Center of the CiRA Foundation. He is a stem cell biologist with over 20 years of research experience, specializing in pluripotent stem cells and cellular reprogramming. He received his PhD in developmental biology from the University of Tokyo in 2009. He then worked as a postdoctoral fellow in Shinya Yamanaka's lab at the Gladstone Institute of Cardiovascular Disease (affiliated with the University of California, San Francisco), where he studied intractable diseases using patient-derived induced pluripotent stem cells (iPSCs) and the molecular mechanisms of iPSC generation. Following this, he was appointed as an assistant professor at the University of Tsukuba, a team leader at the RIKEN BioResource Research Center, and a visiting professor at the University of Tsukuba. He has published more than 50 peer-reviewed articles, including papers in Nature, Cell, and other high-impact journals, with over 5,500 citations in total. Currently, his research focuses on realizing autologous transplantation of iPSC-derived products for cell therapy and utilizing disease-specific iPSC lines for basic research and drug development.

雷蒙德·黃副教授是澳洲眼科研究中心（CERA）及墨爾本大學眼科系的首席研究員。他是一位幹細胞生物學家，擁有超過20年的研究經驗，專注於眼科研究中的細胞重編程和幹細胞。他在莫納什大學完成了幹細胞生物學的博士學位，並獲得加州再生醫學研究所的獎學金，前往美國加州大學爾灣分校進行海外博士後訓練，還獲得訪問學者獎以在美國國立衛生研究院進行培訓。2013年，黃副教授在克蘭伯恩基金會獎學金和MAWA獎學金的支持下加入CERA。他也是Mirugen的創始人及首席科學官，這是一家專注於視網膜基因治療的初創公司。黃副教授在幹細胞和眼科研究領域共同發表了95篇經過同行評審的論文。目前，他的研究重點是利用幹細胞和基因治療來治療視網膜退化。

林陽平博士是CiRA基金會研究與開發中心的單位負責人。他是一位幹細胞生物學家，擁有超過20年的研究經驗，專注於多能幹細胞和細胞重編程。他於2009年在東京大學獲得發展生物學的博士學位。隨後，他在山中伸彌的實驗室（隸屬於加州大學舊金山分校的格拉德斯通心血管疾病研究所）擔任博士後研究員，研究使用患者衍生的誘導多能幹細胞（iPSCs）及iPSC生成的分子機制來探討難治性疾病。之後，他被任命為筑波大學的助理教授、RIKEN生物資源研究中心的團隊負責人，以及筑波大學的訪問教授。他已發表超過50篇經過同行評審的文章，包括在《Nature》、《Cell》等高影響力期刊上的論文，總引用次數超過5,500次。目前，他的研究重點是實現自體移植iPSC衍生產品的細胞治療，並利用疾病特異性iPSC細胞系進行基礎研究和藥物開發。